Previous studies have shown that targeting inhibition of the PI3K-Akt signaling pathway can enhance the radiosensitivity of glioma cells [39], whereas downregulation of the activity of the PI3K/Akt signaling pathway promotes the radiosensitivity of NSCLC and inhibits tumor development [40]. The gene discussed is AKT1; the disease is central nervous system cancer.